Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Peripheral T-cell Lymphoma

Treatments: Drug: Systemic therapy

Study type: Observational

Funder types: Industry

Identifiers

NCT06422247

CA073-1019

Details and patient eligibility

About

The purpose of this study is to describe the therapeutic practices and the prognosis of patients with relapsed or refractory peripheral T-cell lymphoma in Japan

Enrollment: 307 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female participants with a confirmed diagnosis of the specific subtypes of peripheral T-cell lymphoma (PTCL) according to The World Health Organization (WHO) classification of lymphoid neoplasm, 4th edition defined by WHO and International Agency for Research on Cancer (IARC).
• Participates aged ≥18 years of age at diagnosis of PTCL.
• Participates who have been treated with a systemic therapy for PTCL and have initiated a systemic therapy as a second-line therapy for relapsed or refractory PTCL between April 1, 2018 and March 31, 2023.

Exclusion criteria

• Participates who have medical history of peripheral T-cell lymphoma (PTCL) treatment by unapproved drug in Japan as of 31 March 2024 or off-label drug for PTCL in Japan as of 31 March 2024.
• Participates who have medical history of participation to a separately defined registration study for regulatory approval in PTCL.
• Participates who have medical history of PTCL treatment in a separately defined clinical study with intervention by on-label regimen for PTCL.
• Participates judged to be inappropriate for enrollment in this study by the site investigator.

Trial design

307 participants in 1 patient group

Relapsed or refractory peripheral T-cell lymphoma initiating second-line systemic therapy

Treatment:

Drug: Systemic therapy